PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. It is the new clinical name for what was called Polycystic Ovary Syndrome (PCOS). The renaming was announced on 12 May 2026 by the Endocrine Society and 55 partner organizations to better reflect what the condition actually is: a multi-system disorder affecting hormones (polyendocrine), metabolism (insulin resistance), reproductive function (cycles and fertility), skin and hair (acne, hirsutism, scalp hair loss), and mental health (depression, anxiety). PMOS affects around 8 to 13 percent of women of reproductive age, roughly 170 million women worldwide. The condition is lifelong but well-manageable with dietary changes, supplements, lifestyle adjustments, and medications when needed.
What does PMOS stand for?
PMOS stands for Polyendocrine Metabolic Ovarian Syndrome.
- Polyendocrine: the condition affects multiple hormone systems, not just the ovaries.
- Metabolic: insulin resistance, weight regulation, and energy metabolism are involved.
- Ovarian: the reproductive component of the condition.
- Syndrome: a recognised pattern of symptoms that appear together.
The old name (PCOS, Polycystic Ovary Syndrome) was retired because it described ovarian cysts that around 30 percent of patients never have, while ignoring the metabolic, dermatological, and mental health components that most patients do have.
The 5 pillars of PMOS
The new PMOS name explicitly captures the 5 systems the condition affects. Most women have symptoms across 3 or 4 of these pillars.
| Pillar | Common signs | Approx prevalence in PMOS |
|---|---|---|
| Endocrine (hormones) | High androgens (testosterone, DHEA-S), low SHBG, elevated LH/FSH ratio | 60-80% |
| Metabolic (insulin and energy) | Insulin resistance, weight gain at the waist, pre-diabetes, fatty liver | 50-70% |
| Reproductive (cycles and fertility) | Irregular or absent periods, anovulation, fertility challenges | 70-90% |
| Dermatological (skin and hair) | Acne (often jawline), hirsutism, scalp hair thinning, acanthosis nigricans | 40-70% |
| Mental health | Depression, anxiety, eating disorder risk, sleep disruption | 30-60% |
Who gets PMOS?
PMOS affects around 8 to 13 percent of women of reproductive age worldwide, roughly 170 million women. It is the most common endocrine disorder in this age group. The condition often starts becoming visible in late adolescence, with the average diagnosis coming at age 27, after around 7 years of symptoms (the diagnostic delay is one of the reasons the renaming was pushed forward).
Risk factors:
- Family history. PMOS has a strong genetic component. A first-degree relative with PMOS roughly doubles your risk.
- Insulin resistance. Around 70 percent of women with PMOS have insulin resistance, which can develop before other symptoms appear.
- Higher BMI. Higher BMI is associated with more severe PMOS symptoms, though women with normal BMI also commonly have PMOS (often the "lean PMOS" phenotype).
- Certain ethnicities. South Asian, Mediterranean, and Indigenous American women have higher prevalence and often more severe androgenic symptoms.
- Post-hormonal contraception. Some women develop or unmask PMOS symptoms after stopping the pill.
What causes PMOS?
PMOS is multifactorial. No single cause has been identified, but the dominant biological drivers are:
1. Insulin resistance
Cells become less responsive to insulin, so the pancreas produces more to keep blood glucose normal. Chronically elevated insulin raises ovarian androgen production, lowers SHBG (more free testosterone), and contributes to weight gain at the waist. Insulin resistance is present in around 70 percent of women with PMOS.
2. Elevated androgens
The ovaries (and sometimes the adrenal glands) produce more androgens (testosterone, DHEA-S) than they should. The excess androgens drive acne, hirsutism, scalp hair loss, and disrupt ovulation.
3. Disrupted ovulation
The precise hormonal signals needed to mature one egg each month get disrupted. Many small follicles start to develop but none reach full maturity, no egg is released (anovulation), and cycles become irregular or absent.
4. Inflammation
Women with PMOS have elevated inflammatory markers (CRP, IL-6, TNF-alpha). Inflammation amplifies insulin resistance and androgen production, creating a self-reinforcing cycle.
5. Genetic and epigenetic factors
Multiple genes have been linked to PMOS. The condition often runs in families. Epigenetic factors (environmental influences on gene expression, including maternal nutrition during pregnancy) may also contribute.
The 4 PMOS phenotypes
PMOS is not one condition; it is a spectrum with 4 recognised phenotypes that need slightly different management approaches.
| Phenotype | Approx prevalence | Dominant features |
|---|---|---|
| Insulin-resistant | 70% | Insulin resistance + weight at waist + irregular cycles. Most common. |
| Adrenal | 15% | High DHEA-S, often normal weight, stress-driven flares, anxiety prominent. |
| Post-pill | 10% | Symptoms emerged after stopping hormonal contraceptives. Often resolves over 12-18 months. |
| Inflammatory | Variable, often overlaps | Cystic acne, gut issues, food sensitivities, joint pain. |
Take the free phenotype quiz to find out which phenotype matches your symptoms.
How is PMOS diagnosed?
PMOS is diagnosed using the Rotterdam 2003 criteria, which require 2 of 3 features with other conditions ruled out:
- Irregular or absent periods (cycles longer than 35 days, fewer than 8 per year, or skipped for 3+ months).
- Clinical or biochemical hyperandrogenism (acne, hirsutism, scalp hair loss, OR elevated testosterone or DHEA-S on blood test).
- Polycystic ovaries on ultrasound (12+ small follicles in at least one ovary, or ovarian volume above 10 mL).
Mimics to rule out include thyroid dysfunction, hyperprolactinaemia, congenital adrenal hyperplasia, and Cushing syndrome. See our full PMOS diagnosis guide for the complete workup.
How is PMOS treated?
PMOS treatment is layered. The right combination depends on phenotype, severity, and goals (symptom control, fertility, long-term health).
Foundation: dietary and lifestyle changes
- 30/30/40 macro split (30 percent carbs, 30 percent protein, 40 percent fat) per the 2023 International PCOS Guideline.
- Calorie front-loading toward breakfast (the Jakubowicz 2013 pattern reduces fasting insulin by 56 percent).
- 28-35g fibre per day.
- Daily walking 8,000-10,000 steps.
- Strength training 2-3 times per week.
- 7-9 hours of sleep nightly.
Supplements (evidence-graded)
- Inositol 4g/day (40:1 myo to D-chiro ratio): strongest evidence for ovulation and insulin sensitivity.
- Vitamin D3 if deficient. 67-85% of women with PMOS are deficient.
- Omega-3 (EPA+DHA) 2g/day: reduces inflammation and androgens modestly.
- Magnesium glycinate 300-400mg evening: improves sleep and insulin sensitivity.
- Berberine 1,500mg/day for severe insulin resistance.
Medications (when needed)
- Metformin (1,500-2,000mg/day): first-line for insulin resistance, pre-diabetes, BMI above 25 with lifestyle failure, or fertility goals.
- Combined oral contraceptives (drospirenone or cyproterone acetate preferred): for cycle regulation, acne, hirsutism.
- Spironolactone (50-200mg/day): for hirsutism, hair loss, hormonal acne.
- Letrozole: first-line ovulation induction for fertility per 2023 PCOS Guideline.
- GLP-1 receptor agonists (semaglutide, tirzepatide): for BMI 30+ or comorbidities.
What is the difference between PCOS and PMOS?
PCOS and PMOS are the same condition with two names. PCOS was the clinical name from 1935 to 12 May 2026. PMOS is the new name from 12 May 2026 onward. The diagnostic criteria, symptoms, treatments, and dietary recommendations are identical. See our full PCOS vs PMOS comparison.
The renaming was led by the Endocrine Society and 55 partner organizations after an 11-year consensus process. 86 percent of patients and 71 percent of clinicians supported the change in the 2024 community survey of 14,952 stakeholders.
What are the long-term risks of PMOS?
- Type 2 diabetes: around 4 times higher lifetime risk than women without PMOS (2023 Lancet meta-analysis of 1.6 million women).
- Cardiovascular disease: roughly double the lifetime risk.
- Non-alcoholic fatty liver disease (NAFLD): around 60 percent prevalence.
- Endometrial cancer: 2-3 times higher risk, primarily in women with very irregular cycles and no protective withdrawal bleeds.
- Sleep apnoea: around 30 times higher risk than age-matched women without PMOS.
- Depression and anxiety: 3 times and 2.5 times higher rates respectively.
These long-term risks are why metabolic management (insulin, blood pressure, lipids, liver enzymes) is foundational to PMOS care even when reproductive symptoms are controlled.
Can PMOS be cured?
No, PMOS is not currently curable. It is a lifelong condition. But it is highly manageable. With consistent dietary changes, lifestyle adjustments, and medications when needed, most women achieve significant symptom improvement and meaningful long-term risk reduction. Many women describe their PMOS as "well-managed" rather than "cured."
Frequently asked questions
What does PMOS stand for?
PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. It is the new clinical name for PCOS (Polycystic Ovary Syndrome) as of 12 May 2026.
Is PMOS the same as PCOS?
Yes. PMOS is the new clinical name for PCOS introduced 12 May 2026. The condition, diagnostic criteria, symptoms, treatments, and diet are identical. The name change reflects better framing, not new biology.
How common is PMOS?
PMOS affects around 8 to 13 percent of women of reproductive age, roughly 170 million women worldwide. It is the most common endocrine disorder in this age group.
What are the main symptoms of PMOS?
The 5 pillar symptoms: irregular or absent periods (70-90% of women), high androgens producing acne and hirsutism (60-80%), insulin resistance with weight at the waist (50-70%), scalp hair thinning (around 22%), and elevated rates of depression, anxiety, and sleep disruption (30-60%).
How do I know if I have PMOS?
See a primary care doctor, gynaecologist, or endocrinologist if you have any combination of: irregular or absent periods, persistent acne or new facial/body hair growth, unexplained weight gain at the waist, difficulty conceiving, or persistent low mood with these symptoms. Diagnosis uses the Rotterdam 2003 criteria.
Can you have PMOS without polycystic ovaries?
Yes. Around 30 percent of women with PMOS have no visible polycystic ovaries on ultrasound. The Rotterdam diagnostic criteria allow diagnosis without ovarian cysts as long as the other 2 of 3 features are present (irregular periods plus hyperandrogenism). This is one of the main reasons PCOS was renamed PMOS.
Is PMOS hereditary?
PMOS has a strong genetic component. A first-degree relative (mother, sister, daughter) with PMOS roughly doubles your risk. Multiple genes contribute. Environmental and lifestyle factors interact with genetic predisposition.
Can PMOS be reversed?
PMOS cannot be reversed in the sense of being cured, but symptoms can be reduced dramatically. With consistent dietary changes, lifestyle adjustments, and medications when needed, most women achieve significant symptom improvement and long-term risk reduction. Stopping the interventions typically returns symptoms within months.
Start with a personalised PMOS plan
The right plan starts with your phenotype.
Insulin-resistant PMOS needs different food than adrenal PMOS. Take the free 90-second phenotype quiz to find out which of the 4 PMOS phenotypes you fit, then get a personalised PMOS meal plan built around your specific phenotype.
What to read next
- PCOS is now PMOS: the full renaming explainer
- PCOS vs PMOS: what is the difference
- PMOS symptoms across the 5 pillars
- How PMOS is diagnosed
- PMOS diet: what to eat
- Best supplements for PMOS
How this article was researched
Sources include the 12 May 2026 PCOS to PMOS renaming consensus paper in The Lancet, the Endocrine Society announcement and press materials, the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, the 2024 PCOS Renaming Community Survey (14,952 respondents), the 2003 Rotterdam diagnostic criteria, the 2023 Lancet meta-analysis on PCOS and type 2 diabetes, and the 2023 Lancet systematic review on mental health in PCOS. PCOS was renamed PMOS on 12 May 2026; biology and clinical care are unchanged under the new name. This article is informational and not medical advice. See our editorial standards.
Community Comments
Add a comment